By Industry | By Industry Segment | By Services and Suppliers | By Location | By Hotbed | Profile Search

Company Profile


Mallinckrodt Pharmaceuticals 

675 McDonnell Boulevard

Hazelwood  Missouri  63042  U.S.A.
Phone: 314-654-2000 Fax: 314-654-5381


Medical Device


Advanced Magnetics, Inc.  GastroMARK in North America

Company News
Mallinckrodt (MNK) Supports Safe Home Disposal Of Unused Medications 3/10/2015 9:20:07 AM
Mallinckrodt Pharmaceuticals (MNK) To Report First Quarter Fiscal 2015 Results On February 3, 2015 1/6/2015 8:59:22 AM
Mallinckrodt Pharmaceuticals (MNK) Responds To FDA’s Expected Reclassification Of Methylphenidate ER 11/14/2014 6:12:09 AM
Mallinckrodt Pharmaceuticals (MNK)'s Generic ADHD Drug Does Not Measure Up To Johnson & Johnson (JNJ)'s Concerta: FDA 11/14/2014 6:10:49 AM
Mallinckrodt Pharmaceuticals (MNK) Release: New REMS Education Program Helps Increase Safe, Responsible Use Of Opioid Analgesics For Pain Relief 9/8/2014 1:41:18 PM
Nuvo Research Inc. (NRI.TO) Settles Litigation With Mallinckrodt Pharmaceuticals (MNK) 9/8/2014 7:30:10 AM
Mallinckrodt Pharmaceuticals (MNK) Presents 11 Posters With Data On Investigational Opioid, MNK-155, And XARTEMIS™ XR (Oxycodone Hydrochloride And Acetaminophen) Extended Release Tablets (CII) At Painweek 2014 9/5/2014 10:27:16 AM
Mallinckrodt Pharmaceuticals (MNK) To Hold Investor Briefing October 14, 2014, In New York 9/3/2014 1:48:25 PM
Mallinckrodt Pharmaceuticals (MNK) Releases Human Abuse Liability (HAL) Data For Investigational MNK-155, An Extended-Release Hydrocodone/Acetaminophen Combination 9/3/2014 10:24:13 AM
Mallinckrodt Pharmaceuticals (MNK) To Present Data For Investigational And Approved Extended-Release Opioid Combination Medicines At PAINWeek 8/28/2014 10:44:02 AM